Share

May 2019; 6 (3) ArticleOpen Access

Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica

Baptiste Pasquier, Nadja Borisow, Ludwig Rasche, Judith Bellmann-Strobl, Klemens Ruprecht, Thoralf Niendorf, Tobias J. Derfuss, Jens Wuerfel, Friedemann Paul, Tim Sinnecker
First published March 7, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000541
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
748

Share

Article Information

vol. 6 no. 3 e541
DOI: 
https://doi.org/10.1212/NXI.0000000000000541
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received September 4, 2018
  • Accepted in final form November 26, 2018
  • First Published March 7, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Baptiste Pasquier,
    2. Nadja Borisow, MD,
    3. Ludwig Rasche, MD,
    4. Judith Bellmann-Strobl, MD,
    5. Klemens Ruprecht, MD,
    6. Thoralf Niendorf, MD, PHD,
    7. Tobias J. Derfuss, MD,
    8. Jens Wuerfel, MD,
    9. Friedemann Paul, MD* and
    10. Tim Sinnecker, MD*
  1. Baptiste Pasquier,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) ECTRIMS-conference Travel Grant,

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Nadja Borisow, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ludwig Rasche, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Judith Bellmann-Strobl, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaking fees and travel grants from Bayer Healthcare, sanofi-aventis/Genzyme, Merck and Teva Pharmaceuticals

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Klemens Ruprecht, MD,
    6. Scientific Advisory Boards:

    1. (1)sanofi-aventis/Genzyme (2)Novartis (3)Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Bayer Healthcare, travel and speaker honoraria (2)Biogen Idec, travel and speaker honoraria (3)Merck Serono, travel and speaker honoraria (4)sanofi-aventis/Genzyme, travel and speaker honoraria (5)Teva Pharmaceuticals, travel and speaker honoraria (6)Novartis, travel and speaker honoraria (7)Guthy Jackson Charitable Foundation, travel honoraria

    Editorial Boards:

    1. (1) PLOS ONE, Academic Editor, since 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Neurologie in Frage und Antwort, Elsevier, 2000-2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Merck Serono

    Research Support, Government Entities:

    1. (1)German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Thoralf Niendorf, MD, PHD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Siemens Healthcare, Erlangen Germany funding for travel

    Editorial Boards:

    1. Magnetic Resonance Materials in Physics, Biology and Medicine Guest editor for the special issue on ultrahigh field MR 2015-2016 Guest editor for the special issue on fluorine MRI 2018- 2019

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. I am founder and CEO of MRI.TOOLS GmbH, Berlin, Germany

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Siemens Healthcare, Erlangen, Germany

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Tobias J. Derfuss, MD,
    8. Scientific Advisory Boards:

    1. Scientific advisory boards for (1) Biogen (2) Novartis (3) Genzyme (4) Merck (5) Bayer (6) Octapharma (7) GeNeuro (8) Roche (9) Actelion (10) Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. travel and speaker honoraria from (1) Bayer (2) Biogen (3) Merck (4) Novartis (5) Genzyme (6) Roche

    Editorial Boards:

    1. Member of the Editorial board of Plos One

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. My wife is an employee of Novartis.

    Consultancies:

    1. Member of steering committee in Phase II studies by Mitsubishi Pharma and by GeNeuro

    Speakers' Bureaus:

    1. (1) Biogen (2)Novartis (3) Merck

    Other activities:

    1. Member of the Executive board of ECTRIMS (non-profit entity)

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Biogen

    Research Support, Government Entities:

    1. (1)PI of a projected funded by the Swiss National Foundation

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Swiss MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. My wife owns stocks option from Novartis

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Jens Wuerfel, MD,
    9. Scientific Advisory Boards:

    1. 2011: Novartis advisory board 2014: Biogen, Novartis advisory board 2015: Genzyme, Teva advisory board 2016: Genzyme, Roche advisory board 2017: Genzyme, Roche advisory board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 2011: Novartis travel support (AAN) 2012-2016: Bayer, Biogen, Novartis speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. CEO, MIAC AG, Switzerland (non-profit organisation)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. German ministry of education and research (BMBF/KKNMS), subinvestigator, 2013-2016; and the German ministry of economy (BMWi), EXIST program and EU (Horizon2020)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Friedemann Paul, MD* and
    10. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune steering committee

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Tim Sinnecker, MD*
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Actelion, travel support (2) Roche, travel support (3) Biogen, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) MIAC, Basel, Switzerland

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neurologic Clinic and Policlinic (B.P., T.J.D., T.S.), Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland; NeuroCure Clinical Research Center (N.B., L.R., J.B.-S., F.P., T.S.), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (N.B., J.B.-S., K.R., F.P.), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Experimental and Clinical Research Center (F.P.), Charité—Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine; Clinical and Experimental Multiple Sclerosis Research Center (K.R., F.P.), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Berlin Ultrahigh Field Facility (T.N.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Germany; Medical Image Analysis Center AG (J.W., T.S.); and qbig (J.W.), Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
  1. Correspondence
    Dr. Paul friedemann.paul{at}charite.de
View Full Text

Article usage

Article usage: March 2019 to April 2023

AbstractFullPdfSource
Mar 20192041147Highwire
Apr 20191429337Highwire
May 20198139793Highwire
Jun 20191459263Highwire
Jul 2019316322Highwire
Aug 2019418721Highwire
Sep 201985515Highwire
Oct 20199486Highwire
Nov 201933710Highwire
Dec 201911437Highwire
Jan 20207436Highwire
Feb 20202466Highwire
Mar 20206216Highwire
Apr 20206247Highwire
May 202036213Highwire
Jun 20204207Highwire
Jul 20206398Highwire
Aug 20202199Highwire
Sep 20208315Highwire
Oct 202065013Highwire
Nov 20204298Highwire
Dec 20208219Highwire
Jan 202111414Highwire
Feb 202112216Highwire
Mar 20212218Highwire
Apr 202122210Highwire
May 202162812Highwire
Jun 202174016Highwire
Jul 20215158Highwire
Aug 202186112Highwire
Sep 202152420Highwire
Oct 202163022Highwire
Nov 202112918Highwire
Dec 20213135Highwire
Jan 202241615Highwire
Feb 20223166Highwire
Mar 2022214215Highwire
Apr 2022365Highwire
May 20224810Highwire
Jun 202291912Highwire
Jul 20222234Highwire
Aug 20225224Highwire
Sep 202252014Highwire
Oct 202253211Highwire
Nov 2022124621Highwire
Dec 202252112Highwire
Jan 202311335Highwire
Feb 20234257Highwire
Mar 20233398Highwire
Apr 202331220Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles